Cargando…

What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China

Objective: To estimate patient preferences for second-line antihyperglycemic medications in China. Methods: A face to face survey with the best-worst scaling (BWS) choices was administered in patients with diagnosed type 2 diabetes mellitus (T2DM). Study participants were asked to indicate which att...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shimeng, Liu, Jing, Yu, Yijiang, Si, Lei, Tang, Chengxiang, Liu, Zhigang, Chen, Yingyao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733399/ https://www.ncbi.nlm.nih.gov/pubmed/35002736 http://dx.doi.org/10.3389/fphar.2021.802897

Ejemplares similares

Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus
por: Zhu, Wei, et al.
Publicado: (2019)

What Are the Important Factors Influencing the Recruitment and Retention of Doctoral Students in a Public Health Setting? A Discrete Choice Experiment Survey in China
por: Liu, Shimeng, et al.
Publicado: (2021)

Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey
por: Liu, Shimeng, et al.
Publicado: (2023)

Antihyperglycemic activity of Albizzia lebbeck bark extract in streptozotocin-nicotinamide induced type II diabetes mellitus rats
por: Patel, Priyank A., et al.
Publicado: (2015)

Antihyperglycemic and Antihyperlipidemic Effects of Aqueous Extracts of Lannea edulis in Alloxan-Induced Diabetic Rats
por: Banda, Michelo, et al.
Publicado: (2018)

Hypoglycemic and antihyperglycemic activity of Saptarangyadi Ghanavati: An Ayurvedic compound formulation
por: Singh, Kanwar Samrat, et al.
Publicado: (2014)

What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis
por: Li, Yao, et al.
Publicado: (2020)

Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications
por: Tseng, Yi-Ju, et al.
Publicado: (2017)

Antihyperglycemic and antioxidant activity of Clitorea ternatea Linn. on streptozotocin-induced diabetic rats
por: Talpate, Karuna A., et al.
Publicado: (2013)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
por: Zhou, Dongchu, et al.
Publicado: (2022)

Clinical effectiveness of second-line antihyperglycemic drugs on major adverse cardiovascular events: An emulation of a target trial
por: Siriyotha, Sukanya, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences
por: Petrocchi, Serena, et al.
Publicado: (2021)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Shi, Fenghao, et al.
Publicado: (2022)

Treating early psychosis: who, what, and when?
por: Cornblatt, Barbara A., et al.
Publicado: (2005)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
por: Huang, Xiaojie, et al.
Publicado: (2019)

Molecular docking and biochemical validation of (-)-syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside binding to an allosteric site in monoamine transporters
por: Liu, Hanhe, et al.
Publicado: (2022)

Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis
por: Ernest, Jacqueline P., et al.
Publicado: (2021)

Antihyperglycemic effect of thymoquinone and oleuropein, on streptozotocin-induced diabetes mellitus in experimental animals
por: Sangi, Sibghatullah Muhammad Ali, et al.
Publicado: (2015)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
por: Chongqing, Tan, et al.
Publicado: (2021)

Antiobesity and Antihyperglycemic Effects of Ginsenoside Rb1 in Rats
por: Xiong, Ye, et al.
Publicado: (2010)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Polysaccharides from natural resource: ameliorate type 2 diabetes mellitus via regulation of oxidative stress network
por: He, Li-Ying, et al.
Publicado: (2023)

A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus
por: Hauber, A. Brett, et al.
Publicado: (2015)

Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines
por: Hotchkiss, Adam G., et al.
Publicado: (2015)

Shu-Xie decoction alleviates oxidative stress and colon injury in acute sleep-deprived mice by suppressing p62/KEAP1/NRF2/HO1/NQO1 signaling
por: Wang, Mengyuan, et al.
Publicado: (2023)

Corrigendum: Shu-Xie decoction alleviates oxidative stress and colon injury in acute sleep-deprived mice by suppressing p62/KEAP1/NRF2/HO1/NQO1 signaling
por: Wang, Mengyuan, et al.
Publicado: (2023)

Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives
por: Jiao, Shimeng, et al.
Publicado: (2022)

Antihyperglycemic Medications and Cardiovascular Risk Reduction
por: Anderson, Sarah L, et al.
Publicado: (2017)

What do Iranian physicians value most when choosing a specialty? Evidence from a discrete choice experiment
por: Sarikhani, Yaser, et al.
Publicado: (2022)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
por: Fu, Shengya, et al.
Publicado: (2022)

Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review
por: Zhang, Xiao, et al.
Publicado: (2022)

A bibliometric analysis of the 100 most-cited articles on curcumin
por: Zhou, Yan-Xi, et al.
Publicado: (2022)

Ebanga™: The most recent FDA-approved drug for treating Ebola
por: Taki, Elahe, et al.
Publicado: (2023)

How and when does monkeypox (mpox) transmit: Implications for prevention and treatments
por: Yuan, Shu, et al.
Publicado: (2023)

Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review
por: Milonas, Dimitrios, et al.
Publicado: (2019)

Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus
por: Nargesi, Arash A., et al.
Publicado: (2021)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
por: Li, SiNi, et al.
Publicado: (2021)

Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?
por: Cumbo, Cosimo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_da4sdjcl1egsnj4e19t8c9jlhc